Kornitzer Capital Management Inc. KS Makes New $566,000 Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Kornitzer Capital Management Inc. KS acquired a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 33,000 shares of the biotechnology company’s stock, valued at approximately $566,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Creative Planning grew its holdings in shares of ADMA Biologics by 52.0% in the third quarter. Creative Planning now owns 54,947 shares of the biotechnology company’s stock valued at $1,098,000 after acquiring an additional 18,800 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in shares of ADMA Biologics by 7.0% in the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 888 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of ADMA Biologics by 8.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 228,367 shares of the biotechnology company’s stock valued at $4,565,000 after acquiring an additional 17,573 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after acquiring an additional 92,281 shares in the last quarter. Finally, Highland Capital Management LLC bought a new position in shares of ADMA Biologics in the third quarter valued at approximately $227,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on ADMA. Raymond James upped their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright upped their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

Insiders Place Their Bets

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Trading Down 0.6 %

NASDAQ:ADMA opened at $16.07 on Thursday. The company has a market cap of $3.80 billion, a P/E ratio of 57.38 and a beta of 0.75. The stock’s fifty day moving average price is $17.08 and its two-hundred day moving average price is $17.89. ADMA Biologics, Inc. has a 1 year low of $5.02 and a 1 year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.